Albany Molecular Research (AMRI) Tops Q4 EPS by 4c; Guides In-Line

Albany Molecular Research (NASDAQ: AMRI) reported Q4 EPS of $0.40, $0.04 better than the analyst estimate of $0.36. Revenue for the quarter came in at $126.4 million versus the consensus estimate of $133.4 million.

GUIDANCE:

Albany Molecular Research sees FY2016 EPS of $1.00-$1.10, versus the consensus of $1.10.

"Strong performances in each of our businesses led us to finish 2015 with total revenue increasing 45% and adjusted contract margins expanding to 26% for the year," said William S. Marth, AMRI's president and chief executive officer. "Our strong performance demonstrates the effectiveness of our strategy to grow both organically and inorganically, create sustainable revenue and EBITDA, and provide valuable and differentiating services and products for our customers.

2015 was a transformative year for AMRI. We significantly expanded our capabilities in API and drug product and added valuable analytical and testing expertise that our customers are looking for in an increasingly complex regulatory and legal environment. In addition, we expanded our discovery service offerings and continue to advance development programs that will provide us new revenue opportunities.

We have built a sustainable platform for our business and as we enter 2016, we have more visibility on our business than we have ever had in our past. Our priority will be to maximize the value of our acquisitions, continue to drive organic and inorganic growth and deliver the quality, reliable and innovative services and products our customers demand."

For earnings history and earnings-related data on Albany Molecular Research (AMRI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c